In this episode of the "The Top Line," Fierce Pharma's Fraiser Kansteiner and Eric Sagonowsky discuss the 20 most influential people in biopharma. We also cover a new topical gene therapy from Krystal Biotech, the FDA approval of Brixadi to treat patients with opioid use disorder, plus more headlines.
To learn more about the topics in this episode:
- The most influential people in biopharma in 2023
- FDA clears Braeburn's long-acting Brixadi to treat opioid use disorder
- Krystal's Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin disease
- Novo Nordisk pauses Wegovy marketing projects to dampen demand
- It's time for Fierce Biotech's 2023 Fierce 15—nominations are NOW OPEN
"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.